Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s chRDNA genome-editing platform enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of CAR-T cell therapies as off-the-shelf treatments for patients with hematologic malignancies.